ClinicalTrials.gg
CompletedNCT01503450Updated Jan 5, 2012

Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition

A Phase 1 interventional study of Olanzapine OD Tablets 5 mg in Fed, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-05.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.

Read the detailed description

An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fed conditions.

02

Conditions studied

  • Fed
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy human subjects within the age range of 18 to 45 years
  • Non-smokers since at least six months
  • Willingness to provide written to participate in the study
  • Body-mass index of ≥18.5 kg/m2 and ≤ 24.9 kg/m2, with body weight not less than 50 kg
  • Absence of significant disease or abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
  • Normal 12-lead or one with abnormality considered to be clinically insignificant
  • Normal chest X-ray PA view
  • Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol
  • Female Subjects

    • of child bearing potential practicing an acceptable method of for the duration of the study as judged by the investigator(s), such as condoms, foams. Jellies, diaphragm, intrauterine device (IUD), or abstinence, or
    • for at least 1 year, or
    • surgically sterile (bilateral tubal ligation. bilateral oophorectomy, or hysterectomy has been performed on the subject

Exclusion criteria

Exclusion Criteria:

  • Personal / family history of allergy or to olanzapine or allied drugs
  • Past history of anaphylaxis or angioedema
  • Any major illness in the past three months or any ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
  • Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
  • Any cardiac, renal or liver impairment, any other organ or system impairment
  • History of seizure or psychiatric disorders
  • Presence of disease markers of 1 and 2, and hepatitis Band C virus
  • Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [ one glass Wine, half plnt boor, and one measure (one ounce) of spirit).
  • Consumption of xanthine containing derivatives (coffee, tea, cola drinks. chocolate) within 48 hours before check-in of each period
  • Use of any recreational drug or a history of drug addiction
  • Participation in any clinical trial within the past 3 months
  • Inaccessibility of veins in left and right arm
  • Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication
  • Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs Within the last four weeks
  • An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study
  • Consumption of grapefruit- containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods
  • Recent history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to the study
  • Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding
  • Having an occupation or requirement of driving a vehicle or operate a complex machinery before 21 days of taking the drug in both periods
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Olanzapine OD Tablets 5 mg

    Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited

    Drug: Olanzapine OD Tablets 5 mg

  • Active comparator
    Zyprexa Zydis 5 mg Tablets

    Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK

    Drug: Olanzapine OD Tablets 5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence is based on Cmax and AUC parameters

    Time frame: 2 months

07

Study locations

1 site
  • Wellquest Clinical Research
    Mumbai, Maharashtra 400013, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2012
First posted
Jan 4, 2012
Start
Nov 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
Jan 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01503450
Responsible party
Sponsor
First posted
Jan 4, 2012
Start date
Nov 2006
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Jan 5, 2012

Study contacts

Dr. Ghanashyam Rao, MBBS
principal investigator · Wellquest Clinical Research

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion